Skip to main content
OpenTrials
Completed

NCT Number: NCT04618913

Anticoagulation in Patients With Venous Thromboembolism and Cancer

This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect costs (where feasible), and safety and effectiveness outcomes in patients with VTE and active cancer or patients with VTE and history of cancer who initiate anticoagulant treatment with a VKA, LMWH or NOACs.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neoplasms Cardiovascular Diseases Embolism Embolism and Thrombosis Thromboembolism Vascular Diseases Venous Thromboembolism

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Pfizer Investigational Site

London, United Kingdom

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A VTE diagnosis
  • Active cancer or history of cancer
  • Treatment with VKA, NOAC (apixaban, rivaroxaban, dabigatran, edoxaban) or LMWH
  • Age ≥ 18 years at the date of index VTE (Venous thromboembolic)

Exclusion criteria

  • Prior VTE diagnosis
  • Diagnosis of prior atrial fibrillation
  • Inferior Vena Cava (IVC) filter
  • Prior exposure to (OAC) oral anticoagulation or (PAC)parenteral anticoagulation - note: Prophylactic use of (OAC)/(PAC) allowed.
  • Pregnancy
  • More than one (OAC) oral anticoagulation or (PAC) parenteral anticoagulation dispensed on the index date.
  • Patients with less than one day of follow up

Treatment and study plan

Apixaban

Drug

Anticoagulant

Rivaroxaban

Drug

Anticoagulant

Edoxaban

Drug

Edoxaban

dabigatran

Drug

Dabigatran

VKA

Drug

Vitamin K antagonist

LMWH

Drug

Low Molecular Weight Heparin

Primary outcomes

  1. Recurrence of Thromboembolism

    Time frame: 6 Months after treatment began as early as 1/1/2013

    The follow-up period during which outcome events of interest will be identified will run from the day after the index date until the end of the data collection or death, whichever occurs first. As data are updated at different times and frequencies in the different study countries, the date of the end of data collection will be determined after the relevant permissions have been acquired from the respective authorities.

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

VICTORIE (VTE IN CANCER - TREATMENT, OUTCOMES AND RESOURCE USE IN EUROPE)

Acronym: VICTORIE

Important dates

Study start
2020
Primary completion
2026
Study completion
2026
First posted
Nov 6, 2020
Registry last updated
Jul 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.